Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R

Abstract excerpt

BRAF inhibitors (BRAFi) have been approved for the clinical treatment of BRAF-mutant metastatic melanoma. Although initial responses to BRAFi are generally favorable, acquired BRAFi resistance emerges rapidly, resulting in treatment failure. Only some of the underlying mechanisms responsible for BRAFi resistance are currently understood. Here, we showed that the genetic inhibition of histone acetyltransferase 1...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cutaneous Melanoma Detection and Management
• Share to Cytokine Signaling Pathways and Interactions
• Share to Melanoma and MAPK Pathways